La cadena de opciones muestra datos clave de las opciones de acciones de BioRestorative Therapies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioRestorative Therapies..

BioRestorative Therapies (NASDAQ:BRTX) Bolsa, Cadena de Opciones

BioRestorative Therapies

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARDX

ATHA

BFRI

BRTX

CDXC

HALO

LUCY

OCEA

PALI

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Thursday's After-Market Session

Biotech

News

Health Care

General

BioRestorative Therapies Announces Israel Patent Office Has Issued A Notice Of Allowance For A New Patent Application Covering Several Fundamental Aspects Of The Company's Allogeneic, Off-The-Shelf ThermoStem Platform

BioRestorative Therapies Announced That Its Chief Scientist And Vice President Of Research And Development, Francisco Silva, Will Present At The Annual International Federation For Adipose Therapeutics And Science Conference

Roth MKM analyst Jonathan Aschoff maintains BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) with a Buy and raises the price target from $15 to $18.

Price Target

Analyst Ratings

Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.55) by 9.09 percent.

Earnings

Earnings Beats

BioRestorative Therapies Q2 2024 GAAP EPS $(0.50) Beats $(0.55) Estimate

BioRestorative Therapies Announces Notice Of Allowance For Patent Related To Its ThermoStem Platform

WIIM

BioRestorative Therapies shares are trading higher after the company announced it regained compliance with the Nasdaq.

BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with <a href="https://www.benzinga.com/pressreleases/24/06/g39353187/biorestorative-therapies-regains-compliance-with-nasdaq-listing-rule-5250-c-1-reports-first-quarte">listing requirements.&nbsp;</a>
The Details:
BioRestorative Therapies reported a net loss for the first quarter of $2.2 million, or 33 cents per share, compared to a net loss of $7.2 million, or $1.93 per share, from the same period last year. The company reported a loss from operations of $4.1 million, a 29% improvement from the $5.8 million loss from operations for the comparable period of 2023. 
The company also reported it ended the first quarter with cash, cash equivalents, and investments held in marketable securities of $16.4 million.&nbsp;
BioRestorative Therapies shares are moving on heavy trading volume Monday following the announcement. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 3 million shares have been traded in the session, compared to the stock&#8217;s 100-day average of 2.014 million shares.
Related News: <a href="https://www.benzinga.com/news/24/06/39337862/whats-going-on-with-carnivals-stock">What&#8217;s Going On With Carnival&#8217;s Stock?</a>
<h2 class="wp-block-heading">How To Buy BRTX Stock: </h2>
By now you're likely curious about how to participate in the market for BioRestorative Therapies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of BioRestorative Therapies which is trading at $2.23 as of publishing time, $100 would buy you 44.84 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
BRTX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, BioRestorative Therapies shares are up 18.4% at $2.19 at the time of publication Monday.
Image: PublicDomainPictures from Pixabay

What's Going On With BioRestorative Therapies Stock?

BioRestorative Therapies Regains Compliance With Nasdaq Listing Rule

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging higher on Thursday.
The Dow traded down 0.21% to 38,629.82 while the NASDAQ rose 0.26% to 17,654.01. The S&amp;P 500 also rose, gaining, 0.13% to 5,428.07&nbsp; .
Check This Out: <a href="https://www.benzinga.com/news/24/06/39310076/alphabet-dropbox-and-2-other-stocks-insiders-are-selling">Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling</a> 
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Thursday.
In trading on Thursday, industrials shares fell by 0.9%.
Top Headline
Shares of Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) fell around 16% during Thursday&#8217;s session following mixed first-quarter earnings including an 8.9% drop in same store sales.
The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents.
Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares shot up 33% to $1.77 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Shares of Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) got a boost, surging 275% to $2.68 after the company announced that it signed a memorandum of understanding and intends to appoint Bounce Electric 1 Private as its contract manufacturing partner for sales of the i300 in India.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares were also up, gaining 12% to $0.3351 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) shares dropped 18% to $32.35. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Shares of Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) were down 36% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) was down, falling 35% to $0.4443 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/06/39310159/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yie">Uber To Rally Around 38%? Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a> 
Commodities In commodity news, oil traded down 0.1% to $78.47 while gold traded down 1.6% at $2,317.20.
Silver traded down 4.1% to $29.025 on Thursday, while copper fell 1.8% to $4.4840.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.31%, Germany's DAX dipped 1.96% and France's CAC 40 tumbled 1.99%. Spain's IBEX 35 Index fell 1.59%, while London's FTSE 100 slipped 0.63%.
Industrial production in the Eurozone fell by 0.1% month-over-month in April following a revised 0.5% gain in the prior month. The annual inflation rate in Spain accelerated for the third month to 3.6% in May.
Germany&#8217;s wholesale prices declined by 0.7% year-over-year in May compared to a 1.8% fall in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.40%, Hong Kong's Hang Seng Index gaining 0.97%, China's Shanghai Composite Index falling 0.28% and India's S&amp;P BSE Sensex gaining 0.27%.
The Hong Kong Monetary Authority kept its base rate unchanged at 5.75% during its latest meeting.
Economics
<ul>
<li>U.S. initial jobless claims rose by 13,000 to 242,000 in the week ending June 8, compared to market estimates of 225,000.</li>
<li>U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April.</li>
<li>U.S. natural-gas supplies rose 74 billion cubic feet during the week ended June 7, versus market estimates of a 75 billion cubic feet gain.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39310078/top-3-tech-and-telecom-stocks-youll-regret-missing-in-q2">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing In Q2</a>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BURU

CARA

JILL

STSS

ZAPP

S&P 500 Edges Higher; J.Jill Shares Plunge

Shares of Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% <a href="https://www.benzinga.com/news/earnings/24/06/39311023/shining-through-challenges-signet-jewelers-reports-mixed-q1-results-optimistic-outlook">drop in same store sales</a>.
The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents.
Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion.
Signet Jewelers shares dipped 12.5% to $94.81 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares climbed 66.3% to $2.22 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 59.3% to $1.14 after the company announced that it signed a memorandum of understanding and intends to appoint Bounce Electric 1 Private as its contract manufacturing partner for sales of the i300 in India..</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares climbed 39% to $0.4162 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) jumped 35.1% to $0.8101.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) gained 28% to $5.95</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) rose 24% to $2.8999.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 23.6% to $0.8070.</li>
<li>Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) jumped 23% to $2.0050 after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 22.8% to $1.84.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) jumped 22.2% to $8.40. Barnes &amp; Noble Education named Jonathan Shar as new Chief Executive Officer.</li>
<li>John Wiley &amp; Sons, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) rose 19.3% to $42.62 as the company reported results for the fourth quarter and fiscal year ended April 30, 2024.</li>
<li>Longeveron Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares climbed 18.8% to $2.15. Longeveron shares jumped over 120% on Wednesday following the circulation of a Zacks Small Cap Research note valuing the stock at $15.10 per share.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) gained 17.3% to $16.10.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares rose 14.9% to $0.70 after surging 5% on Wednesday.</li>
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) jumped 14.3% to $26.92. Roth MKM analyst Justin Clare maintained American Superconductor with a Buy and raised the price target from $20 to $27.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 14.2% to $0.7450.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) rose gained 14.2% to $1,707.99 after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion.</li>
<li>Bitfarms Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) jumped 12.3% to $2.73. The company on Thursday issued new guidance for 2025 after announcing an agreement to develop power capacity in Pennsylvania.</li>
<li>United Homes Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) gained 12.3% to $7.34.</li>
<li>Grupo Supervielle S.A.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) gained 10.7% to $7.26 after rising 6% on Wednesday.</li>
<li>Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) rose 8.3% to $10.36.</li>
<li>Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) gained 7% to $67.87 following better-than-expected quarterly results.</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 6.7% to $189.30 after CEO Elon Musk said the company&#8217;s shareholder resolutions are passing with significant margins.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares fell 48.8% to $0.27.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) fell 37.1% to $0.4202 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) fell 36.1% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares declined 30.9% to $1.07. DayDayCook shares jumped 198% on Wednesday after the company announced it has acquired Omsom.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) fell 29% to $0.50. CERo Therapeutics completed IND-Enabling activities following successful manufacturing runs for lead compound CER-1236.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) declined 28% to $4.1350.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 26.2% to $0.5712 after surging around 19% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) fell 19% to $0.5899.</li>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) fell 17.8% to $32.48. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Tellurian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NYSE">TELL</a>) dipped 16.5% to $0.6328</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares fell 13.1% to $0.7401 after the company announced it will effect a reverse stock split.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares fell 11.7% to $0.5712 after gaining 10% on Wednesday.</li>
<li>Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) shares fell 11.4% to $44.60 after the company posted downbeat results for its first quarter on Wednesday.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) fell 10.8% to $14.13 after the company revised its 2024 group production guidance down due to the impact of weather events on the Salares Norte project.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) dipped 9.8% to $128.74. Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) fell 6.3% to $10.41.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39311150/top-3-tech-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Tech Stocks That May Fall Off A Cliff This Month</a>

AMSC

AVGO

BITF

BMEA

BNED

CERO

Core Scientific, Inc. - Class A Common Stock

CORZ

IONM

KYTX

LGVN

NWTN

PARA

PLAY

PRFX

PTPI

RGEN

SPCE

SUPV

TELL

TSLA

VANI

WHLR

WLYB

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 20.66% to $0.41. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock fell 47.6% to $0.27 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock decreased by 40.28% to $0.42. The company's market cap stands at $6.3 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) stock declined by 35.97% to $0.44. The company's market cap stands at $23.7 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $64.9 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock fell 13.66% to $1.96. The company's market cap stands at $4.8 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares fell 12.61% to $0.47. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

CYCN

ISPC

KRON

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping by more than 200 points on Thursday.
The Dow traded down 0.60% to 38,481.44 while the NASDAQ rose 0.31% to 17,663.22. The S&amp;P 500 also fell, dropping, 0.05% to 5,418.22 .
Check This Out: <a href="https://www.benzinga.com/news/24/06/39310076/alphabet-dropbox-and-2-other-stocks-insiders-are-selling">Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling</a> 
Leading and Lagging Sectors Information technology shares jumped by 1.2% on Thursday.
In trading on Thursday, industrials shares fell by 1.3%.
Top Headline
Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) gained around 13% during Thursday's session after the company posted stronger-than-expected results for its second quarter.
The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares shot up 45% to $1.93 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Shares of Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) got a boost, surging 200% to $2.15 after the company announced that it signed a memorandum of understanding and intends to appoint Bounce Electric 1 Private as its contract manufacturing partner for sales of the i300 in India.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares were also up, gaining 19% to $0.3557 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) shares dropped 17% to $32.79. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Shares of Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) were down 36% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) was down, falling 37% to $0.4277 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
</ul>
Also Check This Out: W<a href="https://www.benzinga.com/news/24/06/39310159/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yie">all Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a>
Commodities In commodity news, oil traded up 0.1% to $78.61 while gold traded down 1.2% at $2,325.60.
Silver traded down 3.7% to $29.145 on Thursday, while copper fell 1.2% to $4.5115.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.27%, Germany's DAX dipped 1.70% and France's CAC 40 tumbled 1.87%. Spain's IBEX 35 Index fell 1.40%, while London's FTSE 100 slipped 0.73%.
Industrial production in the Eurozone fell by 0.1% month-over-month in April following a revised 0.5% gain in the prior month. The annual inflation rate in Spain accelerated for the third month to 3.6% in May.
Germany&#8217;s wholesale prices declined by 0.7% year-over-year in May compared to a 1.8% fall in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.40%, Hong Kong's Hang Seng Index gaining 0.97%, China's Shanghai Composite Index falling 0.28% and India's S&amp;P BSE Sensex gaining 0.27%.
The Hong Kong Monetary Authority kept its base rate unchanged at 5.75% during its latest meeting.
Economics
<ul>
<li>U.S. initial jobless claims rose by 13,000 to 242,000 in the week ending June 8, compared to market estimates of 225,000.</li>
<li>U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April.</li>
<li>U.S. natural-gas supplies rose 74 billion cubic feet during the week ended June 7, versus market estimates of a 75 billion cubic feet gain.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39310078/top-3-tech-and-telecom-stocks-youll-regret-missing-in-q2">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing In Q2</a>

Gold Down 1%; Broadcom Shares Jump After Upbeat Results

BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed <a href="https://www.benzinga.com/wiim/24/06/39309783/biorestorative-therapies-shares-are-trading-higher-after-the-company-announced-that-it-engaged-in-ad">commercial regenerative medicine company</a>.
What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property.
Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders. 
Currently, there is no guarantee that a license agreement will be made between the two companies.
Related Link: <a href="https://www.benzinga.com/partner/biotech/24/06/39309605/candel-therapeutics-nasdaq-cadl-enlighten-discovery-platform-aims-to-tackle-complexities-of-tumor">Candel Therapeutics&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments</a>
BRTX Price Action: At the time of writing, BioRestorative shares are trading 29% higher at $1.75 per data from Benzinga Pro.
Image: Image via Shutterstock

CADL

Why BioRestorative Therapies Stock Is Moving Higher Thursday

U.S. stocks traded mixed this morning, with the Dow Jones index falling by more than 100 points on Thursday.
Following the market opening Thursday, the Dow traded down 0.36% to 38,574.00 while the NASDAQ rose 0.55% to 17,705.52. The S&amp;P 500 also rose, gaining, 0.19% to 5,431.23.
Check This Out: <a href="https://www.benzinga.com/news/24/06/39310076/alphabet-dropbox-and-2-other-stocks-insiders-are-selling">Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling</a> 
Leading and Lagging Sectors Information technology shares jumped by 1.4% on Thursday.
In trading on Thursday, communication services shares fell by 0.9%.
Top Headline
U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares shot up 60% to $2.1399 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Shares of E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) got a boost, surging 42% to $0.8500.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares were also up, gaining 40% to $0.4181 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares dropped 45% to $0.2862.</li>
<li>Shares of Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) were down 36% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) was down, falling 32% to $0.4631 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/06/39310159/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a>
Commodities In commodity news, oil traded down 0.4% to $78.18 while gold traded down 0.7% at $2,338.80.
Silver traded down 2.7% to $29.445 on Thursday, while copper fell 0.5% to $4.5425.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.7%, Germany's DAX dipped 1% and France's CAC 40 tumbled 1.1%. Spain's IBEX 35 Index fell 0.6%, while London's FTSE 100 slipped 0.3%.
Industrial production in the Eurozone fell by 0.1% month-over-month in April following a revised 0.5% gain in the prior month. The annual inflation rate in Spain accelerated for the third month to 3.6% in May.
Germany&#8217;s wholesale prices declined by 0.7% year-over-year in May compared to a 1.8% fall in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.40%, Hong Kong's Hang Seng Index gaining 0.97%, China's Shanghai Composite Index falling 0.28% and India's S&amp;P BSE Sensex gaining 0.27%.
The Hong Kong Monetary Authority kept its base rate unchanged at 5.75% during its latest meeting.
Economics
<ul>
<li>U.S. initial jobless claims rose by 13,000 to 242,000 in the week ending June 8, compared to market estimates of 225,000.</li>
<li>U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39310078/top-3-tech-and-telecom-stocks-youll-regret-missing-in-q2">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing In Q2</a>

Dow Tumbles Over 100 Points; US Producer Prices Decline In May

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. </li>
<li>JanOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) stock rose 26.07% to $3.24. The company's market cap stands at $37.8 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares increased by 21.62% to $0.85. The market value of their outstanding shares is at $9.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 20.74% to $1.63. The company's market cap stands at $11.0 million. </li>
<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) stock rose 20.22% to $1.84. The company's market cap stands at $61.2 million. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock rose 15.9% to $1.89. The market value of their outstanding shares is at $103.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock fell 46.4% to $0.27 during Thursday's pre-market session. The market value of their outstanding shares is at $2.4 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 31.19% to $0.47. The company's market cap stands at $25.5 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares declined by 20.01% to $1.24. The market value of their outstanding shares is at $42.9 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares declined by 16.31% to $0.45. The market value of their outstanding shares is at $3.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 14.95% to $0.51. The company's market cap stands at $3.8 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) stock declined by 8.48% to $1.62. The market value of their outstanding shares is at $89.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

BNOX

CNTB

NUVO

VTAK

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BioRestorative Therapies shares are trading higher after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders &ndash;
- ThermoStem&reg;&nbsp;is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets &ndash;
- Potential license partner is a leading commercial stage regenerative medicine company &ndash;

BioRestorative Therapies Engages In Advanced Discussions For ThermoStem License With A Regenerative Medicine Firm

Contracts

BioRestorative Therapies Signs Five-Year Supply Agreement With Cartessa; BioRestorative To Supply Cartessa With Finished Vials Of Commercial Product Sold Under Chronos ExoCR Brand

BioRestorative Therapies Announced Its Development Of A Novel Exosome-based Biologic Program Targeting Obesity

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sharps Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/stss-stock-quote/">STSS</a>) stock is up on Thursday after the medical device company announced a <a href="https://finance.yahoo.com/news/sharps-technology-receives-30-million-123000997.html">$30 million purchase order</a> for its specialty copolymer prefillable syringes.



Sharps Technology says this purchase order comes from Nephron Pharmaceuticals. It also notes that this $30 million order represents its first 12 months of syringe purchase commitments.



The Sharps Technology order includes both 10mL and 50mL syringes. These will be manufactured at the company&rsquo;s factory in West Columbia. It&rsquo;s worth noting this location is being acquired by Sharps Technology from Nephron Pharmaceuticals.



Sharps Technology CEO Robert Hayes said the following about the deal.




&ldquo;Once the enhanced deal with Nephron was negotiated and signed, everything began moving at an accelerated pace. Sharps is so pleased that Nephron has been willing to issue this Purchase Order now. It speaks to the collaborative relationship between our companies and the long partnership we want to have with Nephron.&rdquo;




<h2>What&rsquo;s Next for STSS Stock?</h2>



This is only the first of a series of orders that the two companies have planned. Sharps Technology says it should close a deal with Nephron Pharmaceuticals for $200 million and five years by the end of the month.



STSS stock is up 20.5% as of Thursday morning. That comes with some 88 million shares traded. The company&rsquo;s daily average trading volume is about 8.7 million units.



Investors will want to keep reading for more of the most recent stock market news!



We have all of the latest stock market stories traders need to know about on Thursday! A few examples include what&rsquo;s going on with shares of Virgin Galactic&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) stock, Occidental Petroleum&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/oxy-stock-quote/">OXY</a>) stock and BioRestorative Therapies&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/brtx-stock-quote/">BRTX</a>) stock today. All of this info is ready to go at the following links!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/virgin-galactic-spce-stock-falls-on-1-for-20-reverse-stock-split-plans/">Virgin Galactic (SPCE) Stock Falls on 1-for-20 Reverse Stock Split Plans</a></li>



<li><a href="https://investorplace.com/2024/06/warren-buffett-keeps-doubling-down-on-occidental-petroleum-oxy-stock/">Warren Buffett Keeps Doubling Down on Occidental Petroleum (OXY) Stock</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-biorestorative-therapies-brtx-stock-up-42-today/">Why Is BioRestorative Therapies (BRTX) Stock Up 42% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-sharps-technology-stss-stock-up-21-today/">Why Is Sharps Technology (STSS) Stock Up 21% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sharps Technology (STSS) Stock Up 21% Today?

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), retaining the price target ...

Buy Rating Justified by BioRestorative Therapies' Advancements and Market Potential

BioRestorative Therapies regains compliance, reports Q1 2024 results

BioRestorative Therapies (BRTX) has shared an update. Discover the latest update from the financial world: a company has recently shared informatio...

BioRestorative Therapies Issues Financial Update Notice

BioRestorative Therapies GAAP EPS of -$0.50 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioRestorative Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/brtx-stock-quote/">BRTX</a>) just reported results for the second quarter of 2024.<ul><li>BioRestorative Therapies reported earnings per share of -50 cents. This was above the analyst estimate for EPS of -56 cents.</li><li>The company reported revenue of $89,100.</li><li>This was 791% better than the analyst estimate for revenue of $10,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/brtx-stock-earnings-biorestorative-therapies-for-q2-of-2024/">BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q2 2024

BioRestorative Therapies (BRTX) just unveiled an update. The latest press release details from the company will not be automatically included in an...

BioRestorative Therapies Clarifies Press Release Usage in Filings

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report) and keeping the price targ...

Buy Rating Affirmed for BioRestorative Therapies Amid Strong Financials and Clinical Progress

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), with a pri...

Roth MKM Reaffirms Their Buy Rating on BioRestorative Therapies (BRTX)

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-14 at 6.27.53 PM

ABBV

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Press Releases

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

Comments

BioRestorative Therapies

BioRestorative Therapies (BRTX) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL